

Onyx Biotec Ltd.

(Formerly known as Onyx Biotec Pvt. Ltd.)

January 14, 2026

Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra Kurla Complex,
Mumbai-4000051

Symbol: ONYX

Sub: Press Release

Ref: Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please find enclosed a Press Release on *“Dry Injection manufacturing line has received regulatory approval for export to the Democratic Republic of Congo (DRC Congo)”*.

Kindly arrange to disseminate and display the same on your Notice Board for the purpose of information.

Thanking You

Yours Faithfully
For Onyx Biotec Limited

Sanjay Jain
Managing Director
DIN: 02214242

Corp. & Marketing Office

S.C.O-70 2nd Floor,
Sector 30-C Chandigarh - 160030
Tel: 0172-2656384
E-mail : sonyxbiotec@gmail.com
Website : www.onyxbiotec.com

CIN. L24230HP2005PLC028403

Registered Office & Works

Unit- I Vill : Bir Plassi, Ropar-Nalagarh Road,
Nalagarh, Distt. Solan (H.P.) 174101
Tel : 01795-265363, Fax : 01795-265465
Unit- II Village Teliwala, PO. Manjholi,
Tehsil Nalagarh, Solan (H.P.) 174101
E-mail : generalinfo@onyxbiotec.com

Press Release

Dry Injection manufacturing line has received regulatory approval for export to the Democratic Republic of Congo (DRC Congo).

Himachal Pradesh, January 14, 2026

ONYX BIOTEC LIMITED (NSE Emerge: ONYX): Onyx Biotec Limited is pleased to announce that its Dry Injection manufacturing line has received regulatory approval for export to the Democratic Republic of Congo (DRC Congo).

This approval enables the Company to commence exports of dry injectable products to the DRC Congo market, further strengthening Onyx Biotec Limited's presence in regulated and semi-regulated international markets. The development reflects the Company's continued focus on quality compliance, regulatory excellence, and global expansion.

The approval is expected to contribute positively to the Company's export portfolio and supports its long-term growth strategy in the African pharmaceutical markets.

Onyx Biotec Limited remains committed to maintaining the highest standards of manufacturing and regulatory compliance while expanding its global footprint.

Disclaimer

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Onyx Biotec

Onyx Biotec Limited (NSE Emerge: ONYX): Onyx Biotec Ltd. is a leading pharmaceutical company engaged in the manufacture and sale distribution of generic and proprietary pharmaceutical products. Onyx Biotec Ltd. established in 2009, develops, manufactures and distributes generic and branded pharmaceutical products in various forms like (WFI) Water for Injection, Dry Powder Injections, Dry Powder Syrup. We employ a staff of dedicated people who work together to produce drug products that sick people can afford to buy that will treat their illness, make them well, reduce suffering and improve the quality of their lives.

For more information please contact:

Investors:

Lakshya Jain, Whole-time director at generalinfo@onyxbiotec.com/ +91 97805 80615

Registered Office & Works